Uni-Bio Science Group EBIT par action

Que fait Uni-Bio Science Group ? Uni-Bio Science Group Ltd. generates revenue through four segments: in-house chemical pharmaceutical products like Pinapu, in-house biological pharmaceutical products such as GeneTime and GeneSoft, in-house biological pipeline products including Uni-E4 and Uni-PTH, and third-party pharmaceutical products. The company manufactures and sells its own chemical and biological products while also distributing third-party pharmaceuticals. Its primary customers are healthcare providers and pharmaceutical distributors purchasing these branded products. The firm's revenue streams are directly tied to the production and distribution of these specific branded pharmaceuticals across its operational segments. The in-house chemical pharmaceutical segment focuses on products like Pinapu, which is sold to medical institutions and pharmacies. The biological pharmaceutical segment markets GeneTime and GeneSoft for specialized treatments, targeting hospitals and clinics. The biological pipeline segment develops Uni-E4 and Uni-PTH for future commercialization, while third-party pharmaceutical sales involve distributing external brands without direct manufacturing. These segments collectively drive the company's revenue through product sales and distribution agreements. Uni-Bio Science Group's business model relies on both direct manufacturing of its branded pharmaceuticals and third-party product distribution. The company's revenue comes from the sale of Pinapu, GeneTime, GeneSoft, Uni-E4, and Uni-PTH as well as third-party pharmaceuticals. Healthcare institutions and pharmaceutical distributors are the key buyers of these products across all segments, with the in-house products forming the core of the company's revenue generation strategy. Uni-Bio Science Group est l'une des entreprises les plus populaires sur Eulerpool.